Talk:Assessment of the health impacts of H1N1 vaccination/Group B
Pandemrix should not be used because of narcolepsy risk
| Fact discussion: . |
|---|
| Opening statement: Pandemrix should not be used any more anywhere because its narcolepsy risk is too high. NOTE! The time of the statement is September 2010.
Closing statement: Resolution not yet found. (A closing statement, when resolved, should be updated to the main page.) |
| Argumentation:
←--#: . All data compiled to date indicate that pandemic vaccines including Pandemrix match the excellent safety profile of seasonal influenza vaccines, which have been used for more than 60 years. --Oluyemitoyinbo 11:12, 1 April 2011 (EEST) (type: truth; paradigms: science: defence) ←--#: . Adjuvanted vaccines commonly provide a stronger immune response than unadjuvanted vaccines and also provide a broader immune response allowing for some potential drift of the influenza virus (Pandemrix is an adjuvanted vaccine). --Oluyemitoyinbo 11:12, 1 April 2011 (EEST) (type: truth; paradigms: science: defence) ←--#: . The number of cases of side effects of H1N1 vaccines (including Pandemrix) is in line with normal background rates on a population basis, as reported in a recent study European Medicines Agency --Oluyemitoyinbo 11:12, 1 April 2011 (EEST) (type: truth; paradigms: science: defence) ⇤--1: . Despite risks, Pandemrix is an effective vaccine and has clearly net positive effects in countries where emergency treatment is poorly available for severe swine flu cases. --Jouni 23:05, 31 March 2011 (EEST) (type: truth; paradigms: science: attack) ←--2: . The reputation of Pandemrix is globally so poor that it is impossible to use it any more. --Jouni 23:05, 31 March 2011 (EEST) (type: truth; paradigms: science: defence) |